Overview
An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids
Status:
Completed
Completed
Trial end date:
2017-01-17
2017-01-17
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study intends to investigate patient satisfaction of treatment with Ointment (W/O emulsion) formulations of Potency Class II topical corticosteroids (TCs) for atopic dermatitis (AD) patients in Japan. Objectives include measuring patient satisfaction, treatment adherence, itchiness, and AD severity scores.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bayer
LEO PharmaCollaborator:
BayerTreatments:
Diflucortolone
Diflucortolone valerate
Criteria
Inclusion Criteria:- Female and male patients with a diagnosis of atopic dermatitis who are treated with
Fatty Ointment Potency Class II (Very strong class) TCs
- Patients who are scheduled to change the formulation of the Potency Class II TC from
Fatty Ointment to Ointment (Water in Oil; Water per Oil emulsion) as per
investigator's routine treatment practice
- Patients who are aged over 20
- Patients who are able to understand and sign a written informed consent
Exclusion Criteria:
-Patients participating in an investigational program with interventions outside of routine
clinical practice
- Patients with any contraindication to TCs
- Patients who are regarded as ineligible by the investigator
- Patients who are pregnant or breastfeeding
- For Period 2 (Spring-Summer), patients enrolled in the Period 1